Similarly, a subject carrying a Lynch Syndrome mutation in one MMR gene has about 50%–80% lifetime-risk to develop colorectal cancer (in case of a mutation in MLH1 or MSH2, but lower risk is associated with MSH6 and PMS2 mutation carriers), and 15%–70% risk of endometrial cancer in women (Table 3 and [121]). This evidence concerns the gene PMS2 and Lynch syndrome.